Morepen Laboratories Intrinsic Value
Morepen Laboratories intrinsic value. Morepen Laboratories (MOREPENLAB) median intrinsic value is ₹54.12 from 10 valuation models (range ₹41–₹271), vs current price ₹135.29 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Compare with MOREPENLAB fair value to assess whether the stock is under or overvalued.
MOREPENLAB Valuation Methods Summary — DCF, Graham Number & P/E
Morepen Laboratories intrinsic value across 10 models vs current price ₹135.29 — upside/downside and value range per method. Read Morepen Laboratories dividend policy for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹40.59 | ₹32.47 - ₹48.71 | -70.0% | EPS: ₹1.12, Sector P/E: 22x |
| Book Value Method | asset | ₹226.73 | ₹204.06 - ₹249.40 | +67.6% | Book Value/Share: ₹113.36, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹270.58 | ₹243.52 - ₹297.64 | +100.0% | Revenue/Share: ₹179.27, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹120.00 | ₹108.00 - ₹132.00 | -11.3% | EBITDA: ₹132.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹54.12 | ₹43.30 - ₹64.94 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹40.59 | ₹36.53 - ₹44.65 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹40.59 | ₹36.53 - ₹44.65 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹67.64 | ₹60.88 - ₹74.40 | -50.0% | ROE: 5.1%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹53.45 | ₹48.11 - ₹58.80 | -60.5% | EPS: ₹1.12, BVPS: ₹113.36 |
| Dividend Yield Method | dividend | ₹40.59 | ₹36.53 - ₹44.65 | -70.0% | DPS: ₹0.20, Target Yield: 2.5% |
MOREPENLAB Intrinsic Value vs Market Price — All Valuation Models
Morepen Laboratories fair value range ₹41–₹271 vs current market price ₹135.29 across 10 valuation models. For current market price and key ratios, visit Morepen Laboratories share price screener.
MOREPENLAB Intrinsic Value Analysis — Undervalued or Overvalued?
Morepen Laboratories median intrinsic value ₹54.12, current price ₹135.29 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of MOREPENLAB?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Morepen Laboratories (MOREPENLAB) is ₹54.12 (median value). With the current market price of ₹135.29, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹40.59 to ₹270.58, indicating ₹40.59 - ₹270.58.
Is MOREPENLAB undervalued or overvalued?
Based on our multi-method analysis, Morepen Laboratories (MOREPENLAB) appears to be trading above calculated value by approximately 60.0%.
MOREPENLAB Financial Health — Key Ratios vs Industry Benchmarks
Morepen Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.85 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 5.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.02x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
MOREPENLAB Cash Flow Quality — Operating & Free Cash Flow
Morepen Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹33 Cr | ₹-30 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹32 Cr | ₹-129 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹73 Cr | ₹32 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹-91 Cr | ₹-115 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-60 Cr | ₹-76 Cr | Negative Cash Flow | 3/10 |